Format

Send to

Choose Destination
Cancer Invest. 2016 May 27;34(5):213-9. doi: 10.3109/07357907.2016.1174257. Epub 2016 Apr 29.

A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers.

Author information

1
a Sarah Cannon Research Institute , Nashville , TN , USA.
2
b Tennessee Oncology, PLLC , Nashville , TN , USA.
3
c Florida Hospital Cancer Institute , Orlando , FL , USA.
4
d OHC (Oncology Hematology Care) , Cincinnati , OH , USA.
5
e Grand Rapids Oncology Program , Grand Rapids , MI , USA.
6
f Florida Cancer Specialists , Ft. Myers , FL , USA.

Abstract

PURPOSE:

To evaluate efficacy and safety of bevacizumab, pertuzumab, and octreotide depot for advanced neuroendocrine tumors.

METHODS:

Patients received bevacizumab 15 mg/kg and pertuzumab 420 mg IV q21 days with octreotide depot 30 mg IM q28 days.

RESULTS:

Toxicities in 43 patients included diarrhea (63%), fatigue (63%), hypertension (44%), and nausea (44%). Reversible G3 hypertension (26%) and LVEF decline (9%) occurred. 7/43 patients achieved objective response (typical carcinoid, 5; pancreatic NET, 2). Median PFS and OS were 6.5 and 26.4 months, respectively.

DISCUSSION:

Bevacizumab, pertuzumab, and octreotide depot was well-tolerated with a 16% ORR. Results in the well-differentiated carcinoid tumors are thought provoking.

KEYWORDS:

Angiogenesis; Monoclonal antibodies; Pancreatic cancer

PMID:
27127841
DOI:
10.3109/07357907.2016.1174257
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center